Critical Outcome Technologies has received a patent for its advanced oncology drug candidate, from the US Patent and Trademark Office. The patent covers the synergistic effects of combination therapies containing COTI-2 and members of ...
Tags: oncology drug, COTI-2, anti cancer agents
Coronado Biosciences has received notice of allowance for US patent application covering CNDO-109, from the US Patent and Trademark Office (USPTO). The patent is entitled, Method for activating natural killer cells by tumor cell ...
Tags: CNDO-109, cancer cells, AML
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to SkyePharma for a patent application 2012/0177734 of RAYOS (Prednisone) delayed-release tablets. The NOA covers the FDA-approved RAYOS, which uses the ...
Tags: SkyePharma, RAYOS delayed-release tablets, rheumatoid arthritis
Biotech has rceived a notice of allowance from the USPTO for a patent application covering the company's long-acting CTP-enhanced human growth hormone (hGH-CTP). Once the patent is issued, PROLOR would gain additional intellectual ...
Tags: PROLOR, CTP platform, human growth hormone
The United States Patent and Trademark Office (USPTO) has issued notice of allowance for Avanir Pharmaceuticals' patent application covering Nuedexta. The patent application entitled, Pharmaceutical Compositions Comprising ...
Tags: USPTO, patent application, nuedexta, pseudobulbar affect
The US Patent and Trademark Office (USPTO) has granted two new patents including Patent No. 8,793,727 and 8,293,728 to Amarin's ultra pure omega-3 fatty acid product. The patents include application No.12/702,889 and 13/349,153 for ...
Skinvisible Pharmaceuticals has received US patent for combining retinoic acid with its patented polymer delivery system, Invisicare. The patent issued by the United States Patent and Trademark Office (USPTO) under the name of "Methods ...
Tags: Skinvisible, combining retinoic acid, USPTO
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Arrowhead Research's new formulation of dynamic polyconjugate (DPC) siRNA delivery system. The patent application No.13/032,029 covers claims for ...
Tags: siRNA delivery system, US Patent, dynamic polyconjugate, DPC platform
The US Patent and Trademark Office (USPTO) has granted three new patents to A.P. Pharma's new APF530 drug delivery candidate. The company said APF530 drug candidate is being developed for the prevention of both acute- and delayed-onset ...
Tags: US Patent, A.P.Pharma, APF530 drug delivery candidate, New Drug Delivery
The US Patent and Trademark Office (USPTO) has issued two additional patents to AcelRx Pharmaceuticals' sufentanil NanoTab pain products. The patent entitled Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment ...
Tags: AcelRx Pharmaceuticals, NanoTab pain products, two additional patents
The US Patent and Trademark Office(USPTO)has granted two new patents including Patent No.8,252,328 and Patent No.8,252,329 to AcelRx Pharmaceuticals'small-volume oral transmucosal dosage forms. The 8,252,328 patent covers delivery of ...
Tags: two new patents, 328, Patent No.8, 252, 329, AcelRx Pharmaceuticals
JUPITER, Fla., - Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical ...
Tags: U.S.Patent, Dyadic International
The United States Patent and Trademark Office(USPTO)has extended the Spectrum Pharmaceuticals US patent covering Folotyn(pralatrexate injection)for five years. The extension,which was granted through the Hatch-Waxman Act,postpones the ...
Tags: USPTO, Spectrum Folotyn Patent, pralatrexate injection
Unilife Corporation's Unifill ready-to-fill(prefilled)syringe has received patent no.8,167,837 from the US Patent and Trademark Office(USPTO). The patent covers Unilife's proprietary technology,which integrates automatic and ...
Tags: Unilife, US Patent, Prefilled Syringe, Alan Shortall
The US Patent and Trademark Office(USPTO)has granted a Notice of Allowance(NOA)to Silence Therapeutics for claims related to interfering RNA molecules and lipid complexes used in drug delivery. The NOA,which is issued based on the ...
Tags: Silence Therapeutics, RNAi therapeutics, Silence Company, RNA molecules